GlassScriptPhysician profile
Alpesh Korant
NPI 1619281300
$4,598.97
in general payments reported to CMS, 2019-2025
22 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $116 · 2021: $679 · 2022: $867 · 2023: $777 · 2024: $900 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,810.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $932.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $549.73 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $518.09 | 2021-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $436.78 | 2020-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $306.73 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $276.95 | 2021-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $245.62 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $241.53 | 2021-2024 | |
| Melinta Therapeutics, LLC | $194.54 | 2022-2024 | Kimyrsa, Rezzayo, Vabomere |
| E.R. Squibb & Sons, L.L.C. | $176.87 | 2019-2024 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $153.75 | 2019-2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $141.41 | 2024-2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.76 | 2025 | Jardiance, Ofev |
| Amgen INC. | $83.41 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $56.85 | 2024 | Trelegy Ellipta |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $42.94 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $39.06 | 2024 | |
| Bioventus LLC | $21.23 | 2024 | Durolane |
| Lundbeck LLC | $20.60 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $20.00 | 2025 | Gemtesa |
| Allergan, INC. | $18.68 | 2020 | |
| Scpharmaceuticals INC. | $15.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpesh Korant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.